Skip to main content

Advertisement

Log in

Growth hormone insensitivity: diagnostic and therapeutic approaches

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Introduction

Growth hormone resistance defines several genetic (primary) and acquired (secondary) pathologies that result in completely or partially interrupted activity of growth hormone. An archetypal disease of this group is the Laron-type dwarfism caused by mutations in growth hormone receptors. The diagnosis is based on high basal levels of growth hormone, low insulin like growth factor-I (IGF-1) level, unresponsiveness to IGF generation test and genetic testing. Recombinant IGF-1 preparations are used in the treatment

Conclusion

In this article, clinical characteristics, diagnosis and therapeutic approaches of the genetic and other diseases leading to growth hormone insensitivity are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Chernausek SD, Horn JA (1998) Growth hormone resistance: biologic implications. J Endocrinol Invest 21:18–23

    Google Scholar 

  2. Richmond EJ, Rogol AD (2008) Recombinant human insulin-like growth factor-1 therapy for children with growth disorders. Adv Ther 25:1276–1287

    Article  CAS  PubMed  Google Scholar 

  3. Rosenbloom AL (1999) Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. J Pediatr 135:280–289

    Article  CAS  PubMed  Google Scholar 

  4. Rosenbloom AL (2009) Mecasermin (Recombinant human insulin-like growth factor 1). Adv Ther 26:40–54

    Article  CAS  PubMed  Google Scholar 

  5. Laron Z, Pettzelan A, Mannheimer S (1966) Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 2:152–155

    CAS  PubMed  Google Scholar 

  6. Laron Z (1999) Natural hystory of the classical form of primary growth hormone resistance (Laron syndrome). JPEM 12:231–249

    PubMed  Google Scholar 

  7. Johnson LB, Woods KA, Rose SJ, Clark AJL, Savage MO (1998) The broad spectrum of inherited growth hormone insensitivity syndrome. TEM 9:228–232

    Google Scholar 

  8. Yordam N, Kandemir N, Erkul I, Kurtoglu S, Hatun S (1995) Review of Turkish patients with growth hormone insensitivity (Laron type). Eur J Endocrinol 133:539–542

    Article  CAS  PubMed  Google Scholar 

  9. Domone HM, Bengolea SV, Jasper HG, Boisclair YR (2005) Acide-labile subunit deficiency: phenotypic similarities and differences between human and Mouse. J Endocrinol Invest 28(Suppl 5):43–46

    Google Scholar 

  10. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfold R, Savage M, Underwood L (1993) Classification of growth hormone insensitivity syndrome. J Pediatr 122:241

    Article  CAS  PubMed  Google Scholar 

  11. David A, Hwa V, Metherell LA et al (2011) Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 32:472–497

    Article  CAS  PubMed  Google Scholar 

  12. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N (2006) Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol Oxf 65:114–117

    Article  CAS  PubMed  Google Scholar 

  13. Burren CP, Woods KA, Rose SJ et al (2001) Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity. Horm Res 55:125–130

    Article  CAS  PubMed  Google Scholar 

  14. David A, Metherell LA, Clark AJL, Camacho-Hübner C, Savage MO (2005) Diagnostic and therapeutic advances in growth hormone insensitivity. Endocrinol Metab Clin N Am 34:581–595

    Article  CAS  Google Scholar 

  15. Johnston LB, Savage MO (1999) Partial growth hormone insensitivity. JPEM 12:251–257

    PubMed  Google Scholar 

  16. Backeljauw PF, Chernausek SD (2012) The insulin-like growth factors and growth disorders of childhood. Endocrinol Metab Clin N Am 41:265–282

    Article  CAS  Google Scholar 

  17. Blum WF, Cotterill AM, Postelninay MC, Ranke MB, Savage MO, Witon P (1994) Improvement of diagnosis criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Acta Paediatr Suppl 399:117–124

    Article  CAS  PubMed  Google Scholar 

  18. Marzullo P, Buckway C, Pratt KL, Colao A, Guevara-Aguirre J, Rosenfeld RG (2002) Leptin concentrations in GH deficiency: the effect of GH insensitivity. J Clin Endocrinol Metab 87:540–545

    Article  CAS  PubMed  Google Scholar 

  19. Spiliotis BE, Alexandries TK, Karystianos C et al (2009) The insulin-like growth factor-1 (IGF-1) generation test as an indicator of growth hormone status. Hormones 8:117–128

    Article  PubMed  Google Scholar 

  20. Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH (1981) Children with normal-variant short stature: treatment with human growth hormone for six months. N Eng J Med 305:123–131

    Article  CAS  Google Scholar 

  21. Darendeliler F, Ocal C, Bas F (2005) Evaluation of insulin-like factor (IGF-1) and IGF binding protein-3 generation test in short stature. JPEM 18:443–452

    CAS  PubMed  Google Scholar 

  22. Cotterill AM, Camacho-Hubner C, Woods K, Martinelli C, Duqesnoy P, Savage MO (1994) The insulin-like growth factor-1 generation test in the investigation of short stature. Acta Paediatr Suppl 399:128–130

    Article  CAS  PubMed  Google Scholar 

  23. Chyrsis DC, Alexandrides TK, Koromantzou E et al (2001) Novel application of IGF-1 and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassemia. Clin Endocrinol 54:253–259

    Article  Google Scholar 

  24. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG (2001) The IGF-1 generation test revisited: a marker of growth hormone insensitivity. JCEM 86:5176–5183

    CAS  PubMed  Google Scholar 

  25. Buckway CK, Selva KA, Pratt KL, Tjoeng E, Guevara-Aguirre J, Rosenfeld RG (2002) Insulin-like factor binding protein-3 generation as a measure of growth hormone insensitivity. JCEM 87:4754–4765

    CAS  PubMed  Google Scholar 

  26. Turan S, Bereket A, Furman A et al (2007) The effect of economic status on height, insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations in healthy Turkish children. Eur J Clin Nutr 61:752–758

    Article  CAS  PubMed  Google Scholar 

  27. Coutant R, Dörr HG, Gleeson H, Argente J (2012) Limitations of the IGF1 generation test in children with short stature. Eur J Endocrinol 166:351–357

    Article  CAS  PubMed  Google Scholar 

  28. Arman A, Ozon A, Isguven PS, Coker A, Peker I, Yordam N (2008) Novel slice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism. JPEM 21:47–58

    Article  CAS  PubMed  Google Scholar 

  29. Bonioli E, Taro M, LaRosa G et al (2005) Heterozygos mutations of growth hormone receptor gene in children with idiopathic short stature. Growth Hormon IGF Res 15:405–410

    Article  CAS  Google Scholar 

  30. Sobrier ML, Dastot F, Duguesnoy P et al (1997) Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. JCEM 82:435–437

    CAS  PubMed  Google Scholar 

  31. Wit JM, van Duyvenvoorde HA, Scheltinga SA et al (2012) Genetic analysis of short children with apparent growth hormone insensitivity. Horm Res Paediatr 77:320–333

    Article  CAS  PubMed  Google Scholar 

  32. Savage MO, Hwa V, David A, Rosenfeld RG, Metherell LA (2011) Genetic defects in the growth hormone-IGF-1 axis causing growth hormone insensitivity and impaired lineer growth. Front Endocrinol 2:1–12

    Article  Google Scholar 

  33. Laron Z (2013) If one daily injection of IGF-I has the same growth-promoting effect as 2 injections per day, why continue to give two injections? Pediatr Endocrinol Rev 10:277–279

    PubMed  Google Scholar 

  34. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P (1999) Long term traetment of GHIS with IGF-1. Results of the European multicenter study. Horm Res 51:128–134

    Article  CAS  PubMed  Google Scholar 

  35. Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL et al (2006) Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 91:1246–1253

    Article  PubMed  Google Scholar 

  36. Balhara B, Misra M, Levitsky LL (2012) Recombinant human IGF-1 (Insulin-like growth factor) therapy: where do we stand today? Indian J Pediatr 79:244–249

    Article  PubMed  Google Scholar 

  37. Hwa V, Nadeau K, Wit JM, Rosenfeld RG (2011) STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 25:61–75

    Article  CAS  PubMed  Google Scholar 

  38. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V (2007) Defects in growth hormone receptor signaling. Trends Endocrinol Metab 18:134–141

    Article  CAS  PubMed  Google Scholar 

  39. Woods KA, Camacho-Hübner C, Savage MO, Clark AJL (1996) Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor 1 gene. N Eng J Med 335:1363–1367

    Article  CAS  Google Scholar 

  40. Saenger P, Czernichow P, Hughes I, Reiter EO (2007) Small for gestational age: Short stature and beyond. Endocr Rev 28:219–251

    Article  CAS  PubMed  Google Scholar 

  41. Chernausek SD (2006) Mendelian genetic causes of the short child born small for gestational age. J Endocrinol Invest 29:16–20

    Article  CAS  PubMed  Google Scholar 

  42. Domené HM, Bengolea SV, Martínez AS (2004) Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 350:570–577

    Article  PubMed  Google Scholar 

  43. Domené HM, Hwa V, Jasper HG, Rosenfeld RG (2011) Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab 25:101–113

    Article  PubMed  Google Scholar 

  44. Kowarski AA, Schneider J, Ben-Galim E, Weldon VV, Daughaday WH (1978) Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH. J Clin Endocrinol Metab 47:461–464

    Article  CAS  PubMed  Google Scholar 

  45. Ahangari G, Ostadali MR, Rabani A, Rashidian J, Sanati MH, Zarindast MR (2004) Growth hormone antibodies formation in patients treated with recombinant human growth hormone. Int J Immunopathol Pharmacol 17:33–38

    CAS  PubMed  Google Scholar 

  46. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R (1993) Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol Oxf 38:137–142

    Article  CAS  PubMed  Google Scholar 

  47. Lan H, Li W, Fu Z et al (2014) Differential intracellular signalling properties of the growth hormone receptor induced by the activation of an anti-GHR antibody. Mol Cell Endocrinol 390:54–64

    Article  CAS  PubMed  Google Scholar 

  48. Lattuada D, Casnici C, Perego C et al (2000) Monoclonal antibody against human growth hormone receptor. Hybridoma 19:177–183

    Article  CAS  PubMed  Google Scholar 

  49. Cappa M, Loche S (2003) Evaluation of growth disorders in the paediatric clinic. J Endocrinol Invest 26(7 Suppl):54–63

    CAS  PubMed  Google Scholar 

  50. Alagille D, Odievre M, Gautier M, Dommergues JP (1975) Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac failure. J Pediatr 86:63–71

    Article  CAS  PubMed  Google Scholar 

  51. Kim MS, Quintos JB (2008) Mauriac syndrome: growth failure and type 1 diabetes mellitus. Pediatr Endocrinol Rev 5:989–993

    PubMed  Google Scholar 

  52. Ranke MB (1996) Towards a concensus on the definition of idiopathic short stature. Horm Res 45(Suppl 2):64–66

    Article  CAS  PubMed  Google Scholar 

  53. Attie KM (2000) Genetic studies in idiopathic short stature. Curr Opin Pediatr 12:400–404

    Article  CAS  PubMed  Google Scholar 

  54. Kiess W, Kratzsch J, Pfaeffle R (2006) The growth hormone and insulin-like growth factor system in girls and women with Turner syndrome. Int Congr Series 1298:63–70

    Article  Google Scholar 

  55. Binder G, Neuer K, Ranke MB, Wittekindt NE (2005) PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. JCEM 90:5377–5381

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

There is no informed consent.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Hatipoglu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurtoğlu, S., Hatipoglu, N. Growth hormone insensitivity: diagnostic and therapeutic approaches. J Endocrinol Invest 39, 19–28 (2016). https://doi.org/10.1007/s40618-015-0327-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-015-0327-2

Keywords

Navigation